Adam Craig Biography and Net Worth

Chairman of X4 Pharmaceuticals

Adam Craig, MD, PhD, MBA, has served as Executive Chair of X4 since August 2025. Dr. Craig brings extensive life science leadership experience to X4 having served as an independent strategic advisor to multiple life science companies. He was previously Interim Chief Executive Officer at Stratus Therapeutics (formerly Garuda Therapeutics) where he remains on the Board of Directors. Prior to Stratus, he was the Chief Executive Officer of CTI BioPharma, where he led a restructuring, oversaw the approval and launch of its first product, and guided its $1.7 billion acquisition by Sobi. Dr. Craig has also served as Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals and as CMO and Senior Vice President of Chemgenex Pharmaceuticals Ltd. Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. He earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, holds a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School in the United Kingdom.

What is Adam R. Craig's net worth?: The estimated net worth of Adam R. Craig is at least $1.58 million as of October 23rd, 2025. Dr. Craig owns 376,087 shares of X4 Pharmaceuticals stock worth more than $1,575,805 as of May 1st. This net worth evaluation does not reflect any other assets that Dr. Craig may own. Learn More about Adam R. Craig's net worth.
How do I contact Adam R. Craig?: The corporate mailing address for Dr. Craig and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on Adam R. Craig's contact information.
Has Adam R. Craig been buying or selling shares of X4 Pharmaceuticals?: Adam R. Craig has not been actively trading shares of X4 Pharmaceuticals during the last quarter. Most recently, on Thursday, October 23rd, Adam R. Craig bought 86,206 shares of X4 Pharmaceuticals stock. The stock was acquired at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the transaction, the chairman now directly owns 376,087 shares of the company's stock, valued at $1,090,652.30. Learn More on Adam R. Craig's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Mark Baldry (Chief Commercial Officer), Adam Craig (Chairman), Mary Dibiase (COO), Derek Meisner (General Counsel), Adam Mostafa (CFO), Paula Ragan (CEO), and Michael Wyzga (Director). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, X4 Pharmaceuticals insiders bought shares 2 times. They purchased a total of 87,238 shares worth more than $252,556.76. The most recent insider tranaction occured on October, 23rd when Chairman Adam R Craig bought 86,206 shares worth more than $249,997.40. Insiders at X4 Pharmaceuticals own 1.1% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 10/23/2025.

Adam R. Craig Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/23/2025	Buy	86,206	$2.90	$249,997.40	376,087

Adam R. Craig Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $4.19

$4.05

$4.24

50 Day Range

MA: $3.97

$3.16

$4.66

2 Week Range

Now: $4.19

$1.35

$4.83

Volume

246,344 shs

Average Volume

457,117 shs

Market Capitalization

$380.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32